Nonetheless, the LPCTC-iChip platform used here is also adaptable to a “positive selection” mode, including the capture of CTCs by virtue of their expression of EpCAM or other epithelial or tumor-specific epitopes, which may be valuable in specific tumor-targeting contexts. Here, EPCAM is linked to neoplasm.